C4X Discovery Holdings PLC (AIM:C4XD) CEO Clive Dix and chief business officer Bhavna Hunjan speak to Proactive after announcing an exclusive global licence deal with AstraZeneca to develop and commercialise C4X Discovery's NRF2 activator programme.
The deal may ultimately be worth up to $402mln to the drug discovery company, and is structured to provide C4X Discovery with another steady stream of income.